Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks cholesterol absorption. Both elevate serum PCS...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ason, Brandon, Tep, Samnang, Davis, Harry R., Xu, Yiming, Tetzloff, Glen, Galinski, Beverly, Soriano, Ferdie, Dubinina, Natalya, Zhu, Lei, Stefanni, Alice, Wong, Kenny K., Tadin-Strapps, Marija, Bartz, Steven R., Hubbard, Brian, Ranalletta, Mollie, Sachs, Alan B., Flanagan, W. Michael, Strack, Alison, Kuklin, Nelly A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: The American Society for Biochemistry and Molecular Biology 2011
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3284161/
https://ncbi.nlm.nih.gov/pubmed/21262787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M013664
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak